Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Post Operative Pain, Post Operative Nausea and Vomiting
Interventions: IV acetaminophen, placebo; Drug
Lead sponsor: MercyOne Des Moines Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Neurocysticercosis
Interventions: Oxfendazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more

Conditions: Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
Interventions: Exendin 9-39, Microlipid, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ankle Osteoarthritis
Interventions: Axolotl Ambient, "Drug/Placebo: 0.9% Normal Saline"; Biological · Drug
Lead sponsor: Axolotl Biologix; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina

Conditions: Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
Interventions: Thiamine, Normal saline; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hip Pain Chronic, Hip Impingement Syndrome, Hip Injuries, Blood Loss, Femoro Acetabular Impingement
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Injuries, Shock, Traumatic
Interventions: normal saline control, vasopressin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 19 more

Conditions: Vomiting, Nausea, Children, Only
Interventions: Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo; Other · Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 7 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Carotid Artery Diseases, Peripheral Arterial Disease
Interventions: Pegulicianine, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer Female
Interventions: Bupivacaine Hydrochloride, Placebo Drug, Pulsed Electromagnetic Field (PEMF) Device, Placebo Device, Ropivacaine Hydrochloride; Drug · Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Postoperative
Interventions: ropivacaine; Drug
Lead sponsor: Liberman, Eric, D.O.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: Peripheral Arterial Disease
Interventions: Angiotensin 1-7, Saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Insulin, Asp(B28)-, Glucagon, Placebo; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Radiocontrast Nephropathy
Interventions: N-Acetylcysteine (NAC), 0.9% Sodium-chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autonomic Nerve Block
Interventions: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: Lanadelumab, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Vitamin B 12 Deficiency
Interventions: Cyanocobalamin, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
Interventions: Depot medroxyprogesterone acetate, Placebo; Drug · Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Type 1 Diabetes
Interventions: Insulin Degludec, Insulin Glargine, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Malaria (Plasmodium Falciparum)
Interventions: PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo; Biological · Device · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Acetaminophen vs Placebo in the Pre-operative Setting and Outcomes on Post-operative Pain, Nausea and Vomiting

Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

Tranexamic Acid (TXA) in Hip Arthroscopy

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Low Dose Vasopressin in Traumatic Shock

Drug Study of Albuterol to Treat Acute Lung Injury

Inhaled Isopropyl Alcohol for Treatment of Nausea

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

PEMF and PEC Blocks in Mastectomy Reconstruction Patients

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

Angiotensin-(1-7) in Peripheral Arterial Disease

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Sternotomy PIFB Block in Open Heart Surgery

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Effects of Vitamin B12 Treatment in Singers

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

Malaria CVD 36000; Gates INV090205